China Pharma Holdings, Inc.
CPHI Healthcare Drug Manufacturers Specialty & Generic
China Pharma Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.1 million, down 8.49% from fiscal 2024. In the quarter to June 2026, revenue fell 7.56%, EPS grew 75.0%, free cash flow fell 113.6% and total debt fell 2.92%, each against the same quarter a year earlier.
Follow CPHI
China Pharma Holdings, Inc. (CPHI) EV/Sales
As of 16 October 2026, China Pharma Holdings, Inc. (CPHI) trades at a EV/Sales of 8.1×. Over the past ten years it has ranged from 0.3× (December 2023) to 84.6× (July 2026); the current reading is higher than 98% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.0× | 54.05% |
| FY2024 | 1.3× | 199.79% |
| FY2023 | 0.4× | (65.09%) |
| FY2022 | 1.2× | (56.12%) |
| FY2021 | 2.8× | 26.55% |
| FY2020 | 2.2× | 77.16% |
| FY2019 | 1.2× | (0.79%) |
| FY2018 | 1.2× | 19.09% |
| FY2017 | 1.0× | (5.22%) |
| FY2016 | 1.1× | 72.48% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 7.6× | 62.08% |
| Mar 2026 | 4.7× | 138.37% |
| Dec 2025 | 2.0× | (24.42%) |
| Sep 2025 | 2.6× | 59.47% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −19.9× |
| UPC Universe Pharmaceuticals INC compare | −0.2× |
| ZYBT Zhengye Biotechnology Holding Limited compare | n/m |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| AYTU Aytu BioPharma, Inc. compare | 0.3× |
| SCYX SCYNEXIS, Inc. compare | 0.7× |
| CPHI China Pharma Holdings, Inc. | 8.1× |
| TXMD TherapeuticsMD, Inc. compare | 85.1× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)